Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix's Manufacturing Inspection: Items Of Concern Are 'Addressable,' Shouldn't Delay Product Launch

Benzinga.com  May 8, 2017

Ocular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

Business Wire May 8, 2017

Ocular Therapeutix™ Reports First Quarter 2017 Financial Results

Business Wire May 5, 2017

Investor Network: Ocular Therapeutix Inc to Host Earnings Call

Accesswire May 5, 2017

Research Reports Initiation on Biotech Stocks -- Trevena, Ocular Therapeutix, INSYS Therapeutics, and Pain Therapeutics

PR Newswire May 5, 2017

Ocular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Business Wire May 2, 2017

Ocular Therapeutix™ to Report First Quarter 2017 Financial Results

Business Wire May 1, 2017

Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

Business Wire April 24, 2017

Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer

Business Wire April 6, 2017

Biotech Stocks on Investors' Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix

PR Newswire March 28, 2017

20 Biggest Mid-Day Losers For Friday

Benzinga.com  March 17, 2017

New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract Surgery

Business Wire March 15, 2017

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results

Business Wire March 10, 2017

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results

Business Wire March 8, 2017

Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery

Business Wire February 22, 2017

Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences

Business Wire February 9, 2017

Research Reports Coverage on Biotech Stocks -- Idera Pharma, Ocular Therapeutix, Radius Health, and Grifols

PR Newswire January 27, 2017

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  January 24, 2017

Mid-Day Market Update: Genvec Jumps Following Announcement of Acquisition By Intrexon; BT Group Shares Drop

Benzinga.com  January 24, 2017

Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock

Business Wire January 24, 2017